Endocrine Abstracts

PurposePostoperative central diabetes insipidus (PCDI) is one of the complications of transsfenoidal adenomectomy (TSA) in patients with Cushing’s disease. Identification of predictors of PCDI development and clinical course could optimize the management of such patients.AimTo study the prevalence of PCDI in patients with Cushing’s disease after transsphenoidal adenomectomy and to find the risk fact...

Background: Detection of MRI-negative ACTH-producing pituitary adenomas is a challenge inthe management of patients with Cushing’s disease. There are some data on theability of pituitary adenomas to accumulate 18F-fluorodeoxyglucose during the 18F-FDG positron emission tomography and computer tomography (18F-FDG PET/CT). Aim: To study the potential of using a standardized uptake value (SUV) and a tumor &...

Background: Detection of MRI-negative ACTH-producing pituitary adenomas is a challenge in the management of patients with Cushing’s disease. There are some data on the possibility of pituitary adenomas to accumulate 18F-fluorodeoxyglucose (18F-FDG) during the 18F-FDG positron emission tomography and computer tomography (18F-FDG PET/CT).Aim: To study the potential of brain 18F-fluorodeoxyglucose PET/CT for localization of MRI-negative ACTH-producing ...

Introduction: Perioperative assessment of surgical outcome in acromegaly patients is essential due to significant persistence rate even after total adenomectomy. Grade of adenoma invasiveness and basal growth hormone (GH) level in early postoperative period have been considered as important factors.Aim: The aim of our study was to evaluate the correlation between the outcomes of surgery in patients with acromegaly and the grade of adenoma invasion assess...

Introduction: Transsphenoidal surgery (TSS) is the treatment of choice for patients with acromegaly. However, even after radical surgery persistence of acromegaly may remain up to thirty percent by resent studies (Starnoni, 2016). Nadir growth hormone (GH) level less than 1.0 μg/l on an early postoperative oral glucose tolerance test (OGTT) have been suggested as early predictor of surgical remission (Kim 2012). However, the value of this approach remains to be defined.</...

Purpose: Transsphenoidal endoscopic surgery (TSS) is the first-line treatment for Cushing’s disease (CD). Persistence and recurrence of hypercortisolism after TSS considered important problem. In this case search for CD remission predictors is actual.Aim: To study the role of preoperative oral high-dose dexamethasone suppression test (HDDST) in the prognosis of CD remission after TSS.Materials and methods: 60 patients with Cus...

Introduction: Acromegaly is a chronic disorder caused by growth hormone (GH) hyperproduction which leads to significant morbidity and mortality primarily due to cardiovascular and respiratory complications. Pituitary adenoma is the main cause of GH’s hyperproduction. By current guidelines transsphenoidal surgery (TSS) is the first-line treatment in acromegaly patients.Aim: To evaluate the results of TSS in acromegaly patients 6 months after surgery....

Purpose: The postoperative levels of cortisol and ACTH are the most commonly used markers for the prediction of Cushing’s disease (CD) remission after transsphenoidal surgery (TSS). However, there is still no consensus on the collection time and threshold values of basal cortisol and ACTH levels after surgery to predict remission of CD.Aim: To study the significance of early postoperative serum cortisol and plasma ACTH testing in the prognosis of C...

Introduction: Growth hormone (GH) level is a direct marker of active residual adenoma tissue after acromegaly surgery. However, the value of early postoperative GH for prediction of surgical cure in acromegaly has not been established and therefore is not used in everyday clinical practice.Aim: The aim of our work was to study the 24-hour basal postoperative GH level and the nadir of GH level after the oral glucose tolerance test (OGTT) two weeks after s...

Introduction: Prolactinomas are the most common pituitary adenomas. Dopamine agonists (DAs) are the treatment of choice for prolactinomas. Patients with prolactinomas normally are treated in ambulatory. In some patients there are challenges in therapy, and they need to be hospitalized.Objective: To study the clinical features and outcomes of in-patients with prolactinoma.Materials and methods: A retrospective analysis of 40 hospita...